research Non-competitive androgen receptor inhibition in vitro and in vivo
Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
Search
for
Sort by
Research
360-390 / 1000+ results research Editorial comment
Alfuzosin reduces short-term surgery need after catheter removal, but long-term benefits are unclear; combination therapy may help prevent urinary issues.
research Cross-species sensitivity to a novel androgen receptor agonist of potential environmental concern, spironolactone
Spironolactone harms fish reproduction and is more potent in fish than invertebrates, needing environmental monitoring.
research Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario
Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.
research Low dose oral minoxidil and the conundrum of cardiovascular complications
Low dose oral minoxidil can help with hair growth but may cause serious heart problems, so doctors need to be careful.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research Vesicular Carriers for Improved Oral Anticoagulation Competence of Rivaroxaban: In Vitro and In Vivo Investigation
Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
research Alopecia associated with atorvastatin
Atorvastatin may cause hair loss in some people.
research SIÇANLARDA SODYUM VALPROAT KAYNAKLI MİDE HASARI ÜZERİNE RUTİN’İN OKSİDATİF STRES, İNFLAMASYON VE APOPTOZ ÜZERİNDEKİ KORUYUCU ETKİLERİNİN ARAŞTIRILMASI
Rutin may protect against stomach damage caused by sodium valproate.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms.
Alpha-blockers are the most effective and widely used treatment for lower urinary tract symptoms, with minimal side effects.
research Efficacy, safety and tolerability of dutasteride in male patients with male pattern hair Loss
research Increased levels of prostaglandin-like material in the canine blood during arterial hypotension produced by hydralazine, dihydralazine and minoxidil
These drugs raise prostaglandin-like material in dog blood, possibly causing blood vessel widening.